{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:07:07Z","timestamp":1792069627390,"version":"4.4.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/ajg.2017.170","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T08:00:48Z","timestamp":1496736048000},"page":"1495-1505","source":"Crossref","is-referenced-by-count":99,"title":["Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.14309","volume":"112","author":[{"given":"Sehrish","family":"Kamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Cholankeril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepansh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Stave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satheesh","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjaya K","family":"Satapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210210","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.","volume":"44","author":"DAmico","year":"2006","journal-title":"J Hepatol"},{"key":"R2-6-20210210","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.numecd.2007.01.007","article-title":"Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.","volume":"17","author":"Loria","year":"2007","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R3-6-20210210","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10620-009-0738-z","article-title":"Coronary artery disease in patients with liver cirrhosis.","volume":"55","author":"Kalaitzakis","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R4-6-20210210","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.amjcard.2006.01.089","article-title":"Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation.","volume":"98","author":"Tiukinhoy-Laing","year":"2006","journal-title":"Am J Cardiol"},{"key":"R5-6-20210210","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.2013.13805","article-title":"The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.","volume":"310","author":"Murray","year":"2013","journal-title":"JAMA"},{"key":"R6-6-20210210","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1089-3261(03)00024-2","article-title":"Hepatotoxicity of hypolipidemic drugs.","volume":"7","author":"Parra","year":"2003","journal-title":"Clin Liver Dis"},{"key":"R7-6-20210210","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/hep.22402","article-title":"Statins in liver disease: a molehill, an iceberg, or neither?","volume":"48","author":"Argo","year":"2008","journal-title":"Hepatology"},{"key":"R8-6-20210210","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4065\/mcp.2009.0365","article-title":"Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.","volume":"85","author":"Calderon","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"R9-6-20210210","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/597039","article-title":"Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients.","volume":"48","author":"Sun","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R10-6-20210210","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1158\/0008-5472.CAN-04-0866","article-title":"Blocking the RafMEKERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.","volume":"64","author":"Wu","year":"2004","journal-title":"Cancer Res"},{"key":"R11-6-20210210","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1073\/pnas.96.14.7797","article-title":"Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase.","volume":"96","author":"Rao","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"R12-6-20210210","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis.","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"key":"R13-6-20210210","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"key":"R14-6-20210210","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"R15-6-20210210","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R16-6-20210210","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"R17-6-20210210","first-page":"1611","article-title":"Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association.","volume":"150","author":"Taddio","year":"1994","journal-title":"CMAJ"},{"issue":"2","key":"R18-6-20210210","first-page":"MR000005","article-title":"Full publication of results initially presented in abstracts.","author":"Scherer","year":"2007","journal-title":"The Cochrane database of systematic reviews"},{"key":"R19-6-20210210","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R20-6-20210210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R21-6-20210210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.28506","article-title":"Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES.","volume":"64","author":"Simon","year":"2016","journal-title":"Hepatology"},{"key":"R22-6-20210210","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep.27835","article-title":"Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES.","volume":"62","author":"Butt","year":"2015","journal-title":"Hepatology"},{"key":"R23-6-20210210","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00002018-200831040-00006","article-title":"Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study.","volume":"31","author":"Avins","year":"2008","journal-title":"Drug Saf"},{"key":"R24-6-20210210","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","article-title":"Statin use in patients with cirrhosis: a retrospective cohort study.","volume":"59","author":"Kumar","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R25-6-20210210","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2015.07.006","article-title":"Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.","volume":"63","author":"Yang","year":"2015","journal-title":"J Hepatol"},{"key":"R26-6-20210210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2014.08.013","article-title":"Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.","volume":"62","author":"Simon","year":"2015","journal-title":"J Hepatol"},{"key":"R27-6-20210210","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jhep.2015.07.009","article-title":"Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis.","volume":"63","author":"Hsiang","year":"2015","journal-title":"J Hepatol"},{"key":"R28-6-20210210","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis.","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"R29-6-20210210","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ajg.2016.179","article-title":"Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study.","volume":"111","author":"Huang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R30-6-20210210","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1097\/QAD.0000000000001219","article-title":"Statin drugs decrease progression to cirrhosis in HIVhepatitis C virus coinfected individuals.","volume":"30","author":"Oliver","year":"2016","journal-title":"AIDS"},{"key":"R32-6-20210210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","article-title":"Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians.","volume":"340","author":"Rzouq","year":"2010","journal-title":"Am J Med Sci"},{"key":"R33-6-20210210","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/labinvest.2012.106","article-title":"Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats.","volume":"92","author":"Klein","year":"2012","journal-title":"Lab Invest"},{"key":"R34-6-20210210","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/sj.bjp.0704173","article-title":"Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).","volume":"133","author":"Eberlein","year":"2001","journal-title":"Br J Pharmacol"},{"key":"R35-6-20210210","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jhep.2014.05.047","article-title":"Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.","volume":"61","author":"Iwakiri","year":"2014","journal-title":"J Hepatol"},{"key":"R36-6-20210210","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.LAB.0000017365.18894.D3","article-title":"Effects and regulation of connective tissue growth factor on hepatic stellate cells.","volume":"82","author":"Paradis","year":"2002","journal-title":"Lab Invest"},{"key":"R37-6-20210210","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bpg.2011.02.011","article-title":"Anti-fibrogenic strategies and the regression of fibrosis.","volume":"25","author":"Kisseleva","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R38-6-20210210","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.104.525774","article-title":"Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells.","volume":"112","author":"Sen-Banerjee","year":"2005","journal-title":"Circulation"},{"key":"R39-6-20210210","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1084\/jem.20031132","article-title":"KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation.","volume":"199","author":"SenBanerjee","year":"2004","journal-title":"J Exp Med"},{"key":"R40-6-20210210","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.","volume":"58","author":"Marrone","year":"2013","journal-title":"J Hepatol"},{"key":"R41-6-20210210","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"R42-6-20210210","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","article-title":"Natural history of hepatitis C.","volume":"9","author":"Thomas","year":"2005","journal-title":"Clin Liver Dis"},{"key":"R43-6-20210210","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.0409834102","article-title":"Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids.","volume":"102","author":"Kapadia","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R44-6-20210210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.gastro.2010.08.055","article-title":"Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C.","volume":"140","author":"Rao","year":"2011","journal-title":"Gastroenterology"},{"key":"R45-6-20210210","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.22916","article-title":"Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development.","volume":"50","author":"Delang","year":"2009","journal-title":"Hepatology"},{"key":"R46-6-20210210","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat Med"},{"key":"R47-6-20210210","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats.","volume":"46","author":"Abraldes","year":"2007","journal-title":"J Hepatol"},{"key":"R48-6-20210210","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial.","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"key":"R49-6-20210210","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4254\/wjh.v6.i7.504","article-title":"Clinical outcomes of compensated and decompensated cirrhosis: a long term study.","volume":"6","author":"Samonakis","year":"2014","journal-title":"World J Hepatol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000434-201710000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:16:45Z","timestamp":1786547805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201710000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2017.170","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}